Prodrugs for Skin Delivery of Menahydroquinone-4, an Active Form of Vitamin K2(20), Could Overcome the Photoinstability and Phototoxicity of Vitamin K2(20)

The effective delivery of menahydroquinone-4 (MKH), an active form of menaquinone-4 (MK-4, vitamin K2(20)), to the skin is beneficial in the treatment of various skin pathologies. However, its delivery through the application of MK-4 to the skin is hampered due to the photoinstability and phototoxicity of MK-4. This study aimed to evaluate the potential of ester prodrugs of MKH for its delivery into the skin to avoid the abovementioned issues. The ester prodrugs, MKH 1,4-bis-N,N-dimethylglycinate hydrochloride (MKH-DMG) and MKH 1,4-bis-hemisuccinate (MKH-SUC), were prepared using our previously reported methods. Photostability was determined under artificial sunlight and multi-wavelength light irradiation, phototoxicity was determined by intracellular ROS formation and cell viability of UVA-irradiated human epidermal keratinocyte cells (HaCaT), and delivery of MKH into HaCaT cells was assessed by measuring menaquinone-4 epoxide (MKO) levels. MKH prodrugs showed higher photostability than MK-4. Although MK-4 induced cellular ROS and reduced cell viability after UVA irradiation, MKH prodrugs did not affect either ROS generation or cell viability. MKH prodrugs enhanced intracellular MKO, indicating effective delivery of MKH and subsequent carboxylation activity. In conclusion, these MKH prodrugs show potential for the delivery of MKH into the skin without photoinstability and phototoxicity.

[1]  K. Ohe,et al.  Antitumor Effects and Delivery Profiles of Menahydroquinone-4 Prodrugs with Ionic or Nonionic Promoiety to Hepatocellular Carcinoma Cells , 2018, Molecules.

[2]  L. Marson,et al.  Biotransformation Capacity of Carboxylesterase in Skin and Keratinocytes for the Penta-Ethyl Ester Prodrug of DTPA , 2016, Drug Metabolism and Disposition.

[3]  A. Hemmati,et al.  Topical vitamin K1 promotes repair of full thickness wound in rat , 2014, Indian journal of pharmacology.

[4]  C. Sonetto,et al.  Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. , 2014, Clinical colorectal cancer.

[5]  A. Luch,et al.  Esterase activity in excised and reconstructed human skin--biotransformation of prednicarbate and the model dye fluorescein diacetate. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  K. Nakagawa,et al.  Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme , 2010, Nature.

[7]  J. Ocvirk.  Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream , 2010, Radiology and oncology.

[8]  A. Chan,et al.  Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors , 2009, The Annals of pharmacotherapy.

[9]  H. Arai,et al.  Squalene as a target molecule in skin hyperpigmentation caused by singlet oxygen. , 2009, Biological & pharmaceutical bulletin.

[10]  R. Perez-soler,et al.  Skin toxicities associated with epidermal growth factor receptor inhibitors , 2009, Targeted Oncology.

[11]  M. Bentley,et al.  Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  R. Voorman,et al.  Comparison of Skin Esterase Activities from Different Species , 2006, Pharmaceutical Research.

[13]  J. Wirz,et al.  Primary photoreactions of phylloquinone (vitamin K_1) and plastoquinone-1 in solution , 2003, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[14]  L. Baumann,et al.  The effects of topical vitamin K on bruising after laser treatment. , 2002, Journal of the American Academy of Dermatology.

[15]  M. Grossman,et al.  Effects of topical vitamin K and retinol on laser-induced purpura on nonlesional skin. , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[16]  H. Iwasaki,et al.  Prodrug for bioreductive activation-independent delivery of menahydroquinone-4: human liver enzymatic activation and its action in warfarin-poisoned human liver. , 1999, Biological & pharmaceutical bulletin.

[17]  T. Sendo,et al.  Vitamin K Prodrugs: 2. Water-Soluble Prodrugs of Menahydroquinone-4 for Systemic Site-Specific Delivery , 1995, Pharmaceutical Research.

[18]  R. Teraoka,et al.  Stabilization-oriented preformulation study of photolabile menatetrenone (vitamin K2) , 1993 .

[19]  R. Yamamoto,et al.  [Photo-degradation and stabilization of vitamin K1. I. Degradation product in ethanol and in non-ionic surfactant solution]. , 1967, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[20]  T. Sendo,et al.  Vitamin K Prodrugs: 1. Synthesis of Amino Acid Esters of Menahydroquinone-4 and Enzymatic Reconversion to an Active Form , 2004, Pharmaceutical Research.